Imaging of hypoxia-driven gene expression in an orthotopic liver tumor model

The purpose of this study was to monitor hypoxia in an orthotopic liver tumor model using a hypoxia-sensitive reporter imaging system and to image enhanced gene expression after clamping the hepatic artery. C6 and RH7777 Morris hepatoma cells were transduced with a triple reporter gene (HSV1-tk/green fluorescent protein/firefly luciferase—triple fusion), placed under the control of a HIF-1–inducible hypoxia responsive element (HRE). The cells showed inducible luciferase activity and green fluorescent protein expression in vitro. Isolated reporter-transduced Morris hepatoma cells were used to produce tumors in livers of nude rats, and the effect of hepatic artery clamping was evaluated. Tumor hypoxia was shown by immunofluorescence microscopy with the hypoxia marker EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl acetamide)] and the fluorescent perfusion marker Hoechst 33342, and by pO2 electrode measurements. For tumor hypoxia imaging with the HRE-responsive reporter, both luciferase bioluminescence and [18F]2′-fluoro-2′-deoxyarabinofuranosyl-5-ethyluracil positron emission tomography was done, and the presence of hypoxia in Morris hepatoma tumors were successfully imaged by both techniques. Transient clamping of the hepatic artery caused cessation of tumor perfusion and severe hypoxia in liver tumors, but not in adjacent liver tissue. These results show that the orthotopic reporter-transduced RH7777 Morris hepatomas are natively hypoxic and poorly perfused in this animal model, and that the magnitude of hypoxia can be monitored using a HRE-responsive reporter system for both bioluminescence and positron emission tomography imaging. However, the severity of tumor ischemia after permanent ligation of the hepatic artery limits our ability to image severe hypoxia in this animal model. [Mol Cancer Ther 2007;6(11):2900–8]

[1]  P. Vaupel,et al.  Hypoxia in cancer: significance and impact on clinical outcome , 2007, Cancer and Metastasis Reviews.

[2]  David L. Schwartz,et al.  Tumor Hypoxia Imaging with [F-18] Fluoromisonidazole Positron Emission Tomography in Head and Neck Cancer , 2006, Clinical Cancer Research.

[3]  S. Fan,et al.  High doses of tyrosine kinase inhibitor PTK787 enhance the efficacy of ischemic hypoxia for the treatment of hepatocellular carcinoma: dual effects on cancer cell and angiogenesis , 2006, Molecular Cancer Therapeutics.

[4]  J. Pouysségur,et al.  Hypoxia signalling in cancer and approaches to enforce tumour regression , 2006, Nature.

[5]  A. Heerschap,et al.  Hypoxia in relation to vasculature and proliferation in liver metastases in patients with colorectal cancer. , 2006, International journal of radiation oncology, biology, physics.

[6]  N. Petrelli,et al.  Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Dewhirst,et al.  Spatial heterogeneity and oxygen dependence of glucose consumption in R3230Ac and fibrosarcomas of the Fischer 344 rat. , 2005, Cancer research.

[8]  Vladimir Ponomarev,et al.  Molecular Imaging of Temporal Dynamics and Spatial Heterogeneity of Hypoxia-Inducible Factor-1 Signal Transduction Activity in Tumors in Living Mice , 2004, Cancer Research.

[9]  W. Denny Prospects for hypoxia-activated anticancer drugs. , 2004, Current Medicinal Chemistry - Anti-Cancer Agents.

[10]  A. Giaccia,et al.  Hypoxic gene expression and metastasis , 2004, Cancer and Metastasis Reviews.

[11]  H. Federoff,et al.  Utilizing Tumor Hypoxia to Enhance Oncolytic Viral Therapy in Colorectal Metastases , 2004, Annals of surgery.

[12]  R. Blasberg,et al.  A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  O. Greco,et al.  Prodrugs in genetic chemoradiotherapy. , 2003, Current pharmaceutical design.

[14]  E. Rofstad,et al.  Temporal heterogeneity in oxygen tension in human melanoma xenografts , 2003, British Journal of Cancer.

[15]  R. Blasberg,et al.  Cytoplasmically retargeted HSV1-tk/GFP reporter gene mutants for optimization of noninvasive molecular-genetic imaging. , 2003, Neoplasia.

[16]  A. Harris,et al.  Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. , 2002, International journal of radiation oncology, biology, physics.

[17]  D. Hedley,et al.  Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  C. Koch,et al.  Hypoxic Heterogeneity in Human Tumors: EF5 Binding, Vasculature, Necrosis, and Proliferation , 2001, American journal of clinical oncology.

[19]  A. Harris,et al.  Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. , 2001, Cancer research.

[20]  T. Hunter,et al.  Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. , 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[21]  M. Marangolo,et al.  Global approach to hepatic metastases from colorectal cancer: indication and outcome of intra-arterial chemotherapy and other hepatic-directed treatments , 2000, Medical oncology.

[22]  S M Evans,et al.  Detection of hypoxia in human squamous cell carcinoma by EF5 binding. , 2000, Cancer research.

[23]  D A Hilton,et al.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.

[24]  J R Griffiths,et al.  The OxyLite: a fibre-optic oxygen sensor. , 1999, The British journal of radiology.

[25]  P Vaupel,et al.  Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. , 1996, Cancer research.

[26]  C. Koch,et al.  Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors. , 1996, The Journal of pharmacology and experimental therapeutics.

[27]  R. Blasberg,et al.  Imaging the expression of transfected genes in vivo. , 1995, Cancer research.

[28]  M. Buyse,et al.  Hepatic artery ligation with and without portal infusion of 5-FU. A randomized study in patients with unresectable liver metastases from colorectal carcinoma. The E.O.R.T.C. Gastrointestinal Cancer Cooperative Group (G.I. Group). , 1991, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[29]  P. Loehrer Relation Between Medicare Screening Reimbursement and Stage at Diagnosis for Older Patients With Colon Cancer , 2008 .

[30]  A. Giaccia,et al.  Hypoxia, gene expression, and metastasis , 2007, Cancer and Metastasis Reviews.

[31]  É. Vinet,et al.  Regional treatment of metastasis: surgery of colorectal liver metastases. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.